An experimental drug was effective against malaria in a new study, potentially offering a much-needed buffer against the rising threat of drug resistance.
The drug, known as GanLum, is made by Swiss pharmaceutical giant Novartis. In a late-stage trial, it worked about as well as existing treatments against malaria – but it was also highly effective against mutant strains that show signs of resistance to the current drugs.
